The DOI matches its Crossref record; 288 of the 288 references it cites were found in a registry or an index.
The ErbB/HER family of protein-tyrosine kinases and cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–288 of 288
Deciphering the Structural Basis of Eukaryotic Protein Kinase Regulation
Meharena, H. S., Chang, P., Keshwani, M. M., Oruganty, K., Nene, A. K., Kannan, N., Taylor, S. S., & Kornev, A. P. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001680 · Cited by 208
Bocharov, E. V., Mineev, K. S., Volynsky, P. E., Ermolyuk, Y. S., Tkach, E. N., Sobol, A. G., Chupin, V. V., Kirpichnikov, M. P., Efremov, R. G., & Arseniev, A. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709202200 · Cited by 208
Protein kinase biochemistry and drug discovery
Schwartz, P. A., & Murray, B. W. (2011) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2011.07.004 · Cited by 201
Recognition of nuclear targeting signals by Karyopherin-β proteins
Xu, D., Farmer, A., & Chook, Y. M. (2010) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2010.09.008 · Cited by 197
Ligand efficiency and fragment-based drug discovery
Bembenek, S. D., Tounge, B. A., & Reynolds, C. H. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.11.007 · Cited by 196
The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand
Bouyain, S., Longo, P. A., Li, S., Ferguson, K. M., & Leahy, D. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507591102 · Cited by 192
Wang, S.-C., & Hung, M.-C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2813 · Cited by 190
Structural Basis for Negative Cooperativity in Growth Factor Binding to an EGF Receptor
Alvarado, D., Klein, D. E., & Lemmon, M. A. (2010) · Cell · doi:10.1016/j.cell.2010.07.015 · Cited by 189
Crystal Structure of Human Protein-tyrosine Phosphatase SHP-1
Yang, J., Liu, L., He, D., Song, X., Liang, X., Zhao, Z. J., & Zhou, G. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210430200 · Cited by 173
Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Phillips, K.-A., Milne, R. L., Rookus, M. A., Daly, M. B., Antoniou, A. C., Peock, S., Frost, D., Easton, D. F., Ellis, S., Friedlander, M. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.8313 · Cited by 171
Protein kinase Cε makes the life and death decision
Basu, A., & Sivaprasad, U. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.04.008 · Cited by 167
Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines
Wakeling, A. E., Barker, A. J., Davies, D. H., Brown, D. S., Green, L. R., Cartlidge, S. A., & Woodburn, J. R. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01803785 · Cited by 166
Ng, S. S. W., Tsao, M., Nicklee, T., & Hedley, D. W. (2002) · PubMed · Cited by 164
BRCA mutations in the management of breast cancer: the state of the art
Narod, S. A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.166 · Cited by 161
Mechanism for activation of mutated epidermal growth factor receptors in lung cancer
Brewer, M. R., Yun, C., Lai, D., Lemmon, M. A., Eck, M. J., & Pao, W. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220050110 · Cited by 160
Paine, M. F., Widmer, W. W., Hart, H. L., Pusek, S. N., Beavers, K. L., Criss, A. B., Brown, S. S., Thomas, B. F., & Watkins, P. B. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.5.1097 · Cited by 160
Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin
Lilja, J. J., Neuvonen, M., & Neuvonen, P. J. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02095.x · Cited by 157
Liu, H., Wu, Y., Lv, T., Yao, Y.-W., Xiao, Y., Yuan, D., & Song, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055128 · Cited by 156
Clinical outcomes in non‐small‐cell lung cancer patients with EGFR mutations: pooled analysis
Paz-Ares, L. G., Soulières, D., Melezínek, I., Moecks, J., Keil, L., Mok, T. S. K., Rosell, R., & Klughammer, B. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00991.x · Cited by 154
Mi, L.-Z., Lu, C., Li, Z., Nishida, N., Walz, T., & Springer, T. A. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2092 · Cited by 154
Biomarker discovery: A proteomic approach for brain cancer profiling
Khalil, A. A. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2007.00374.x · Cited by 149
Atomic structure of the GCSF–receptor complex showing a new cytokine–receptor recognition scheme
Aritomi, M., KUNISHIMA, N., Okamoto, T., Kuroki, R., Ota, Y., & Morikawa, K. (1999) · Nature · doi:10.1038/44394 · Cited by 148
A single ligand is sufficient to activate EGFR dimers
Liu, P., Cleveland, T. E., Bouyain, S., Byrne, P. O., Longo, P. A., & Leahy, D. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201114109 · Cited by 148
Gotoh, N., Tojo, A., Hino, M., Yazaki, Y., & Shibuya, M. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)90812-y · Cited by 143
Intestinal First-Pass Metabolism of CYP3A4 Substrates
Kato, M. (2008) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.23.87 · Cited by 141
Mineev, K. S., Bocharov, E. V., Pustovalova, Y. E., Bocharova, O. V., Chupin, V., & Arseniev, A. S. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.05.016 · Cited by 139
Xia, L., Wang, L., Chung, A. S., Ivanov, S., Ling, M. Y., Dragoi, A. M., Platt, A., Gilmer, T., Fu, X.-Y., & Chin, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202823200 · Cited by 137
Treatment selection in metastatic renal cell carcinoma: expert consensus
Escudier, B. J., Szczylik, C. A., Porta, C., & Gore, M. E. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.59 · Cited by 136
Umebayashi, K., Stenmark, H., & Yoshimori, T. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-10-0988 · Cited by 131
Structure and Dynamic Regulation of Abl Kinases*
Panjarian, S. B., Iacob, R. E., Chen, S., Engen, J. R., & Smithgall, T. E. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.438382 · Cited by 130
Trafficking of receptor tyrosine kinases to the nucleus
Carpenter, G. F., & Liao, H. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.09.027 · Cited by 130
Classical PKC isoforms in cancer
Martiny‐Baron, G., & Fabbro, D. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.04.001 · Cited by 129
Localization of epidermal growth factor receptor in hepatocyte nuclei
Marti, U., Burwen, S. J., Wells, A. H., Barker, M. E., Huling, S. L., Feren, A. M., & Jones, A. L. (1991) · Hepatology · doi:10.1002/hep.1840130104 · Cited by 129
STI-571: an anticancer protein-tyrosine kinase inhibitor
Roskoski, R. J. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.055 · Cited by 127
Self-citationStructural basis for the transforming activity of human cancer-related signaling adaptor protein CRK
Kobashigawa, Y., Sakai, M., Naito, M., Yokochi, M., Kumeta, H., Makino, Y., Ogura, K., Tanaka, S., & Inagaki, F. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1241 · Cited by 125
Blumenthal, G. M., Scher, N. S., Cortazar, P., Chattopadhyay, S., Tang, S. W., Song, P., Liu, Q., Barnett-Ringgold, K., Pilaro, A. M., Tilley, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1212 · Cited by 123
Tamás, P., Solti, Z., Bauer, P., Illés, A., Sipeki, S., Bauer, A. J., Faragó, A., Downward, J., & Buday, L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207555200 · Cited by 119
Shepard, H. M., Brdlik, C. M., & Schreiber, H. W. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36049 · Cited by 119
Fox, I. J., & Kornblum, H. I. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20381 · Cited by 116
The EGF receptor: structure, regulation and potential role in malignancy.
Thompson, D. M., & Gill, G. N. (1985) · PubMed · Cited by 116
Wood, E. R., Shewchuk, L. M., Ellis, B., Brignola, P. S., Brashear, R. L., Caferro, T. R., Dickerson, S. H., Dickson, H. D., Donaldson, K. H., Gaul, M. D., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708281105 · Cited by 113
Massarelli, E., Johnson, F. M., Erickson, H. S., Wistuba, I. I., & Papadimitrakopoulou, V. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.01.018 · Cited by 110
Effect of re-treatment with gefitinib (‘Iressa’, ZD1839) after acquisition of resistance
Kurata, T., Tamura, K., Kaneda, H., Nogami, T., Uejima, H., Asai, G., Nakagawa, K., & Fukuoka, M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdh006 · Cited by 107
Ras-GTPase Activating Protein (GAP): A Putative Effector for Ras
Tocqué, B., Delumeau, I., Parker, F., Maurier, F., Multon, M.-C., & Schweighoffer, F. (1997) · Cellular Signalling · doi:10.1016/s0898-6568(96)00135-0 · Cited by 104
ADAM17, shedding, TACE as therapeutic targets
Rose‐John, S. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.01.012 · Cited by 102
Tamburrino, A., Piro, G., Carbone, C., Tortora, G., & Melisi, D. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00056 · Cited by 102
Yano, S., Nakataki, E., Ohtsuka, S., Inayama, M., Tomimoto, H., Edakuni, N., Kakiuchi, S., Nishikubo, N., Muguruma, H., & Sone, S. (2005) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504005775082020 · Cited by 99
Nuclear Signaling by Receptor Tyrosine Kinases: The First Robin of Spring
Schlessinger, J., & Lemmon, M. A. (2006) · Cell · doi:10.1016/j.cell.2006.09.013 · Cited by 98
The Type 1 growth factor receptors and their ligands considered as a complex system.
Gullick, W. J. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080075 · Cited by 97
Bailey, R., Kris, M. G., Wolf, M., Kay, A., Averbuch, S. D., Askaa, J., Janas, M. S., Schmidt, K., & Fukuoka, M. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)91900-3 · Cited by 95
Köhne, C., Hofheinz, R., Mineur, L., Letocha, H., Greil, R., Thaler, J., Fernebro, E., Gamelin, E. C., DeCosta, L., & Karthaus, M. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1061-6 · Cited by 83
Agazie, Y. M., & Hayman, M. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210670200 · Cited by 83
Crystal Structure of Human Epidermal Growth Factor and Its Dimerization
Lü, H., Chai, J., Li, M., Huang, B.-R., He, C.-H., & Bi, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102874200 · Cited by 82
Colombo, M., Corsi, F., Foschi, D., Mazzantini, E., Mazzucchelli, S., Morasso, C., Occhipinti, E., Polito, L., Prosperi, D., Ronchi, S., et al. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.01.013 · Cited by 80
Zhang, Q., Park, E., Kani, K., & Landgraf, R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200105109 · Cited by 80
Domagala, T., Konstantopoulos, N., Smyth, F. E., Jorissen, R. N., Fabri, L., Geleick, D., Lax, I., Schlessinger, J., Sawyer, W. H., Howlett, G. J., et al. (2000) · Growth Factors · doi:10.3109/08977190009003231 · Cited by 79
Tenev, T., Böhmer, S., Kaufmann, R., Frese, S., Bittorf, T., Beckers, T., & Böhmer, F. (2000) · European Journal of Cell Biology · doi:10.1078/s0171-9335(04)70029-1 · Cited by 77
Parast, C. V., Mroczkowski, B., Pinko, C., et al. (1998) · Biochemistry · doi:10.1021/bi981291f · Cited by 75
Rexer, B. N., Ghosh, R., Narasanna, A., Estrada, M. V., Chakrabarty, A., Song, Y., Engelman, J. A., & Arteaga, C. L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1038 · Cited by 73
Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour
Deng, L., Zhang, J., Wu, T., & Lawrie, T. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005196.pub4 · Cited by 71
SHP-1 in Cell-Cycle Regulation
López‐Ruiz, P., Rodríguez‐Ubreva, J., Cariaga-Martínez, A. E., Cortés, M. A., & Colás, B. (2011) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152011794941154 · Cited by 69
Molecular Mechanism for SHP2 in Promoting HER2-induced Signaling and Transformation
Zhou, X., & Agazie, Y. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900020200 · Cited by 68
Macdonald-Obermann, J. L., Piwnica-Worms, D. R., & PIKE, L. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111316109 · Cited by 68
Two GxxxG-Like Motifs Facilitate Promiscuous Interactions of the Human ErbB Transmembrane Domains
Escher, C., Cymer, F., & Schneider, D. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.04.002 · Cited by 62
Emerging pathways and future targets for the molecular therapy of pancreatic cancer
Vaccaro, V., Melisi, D., Bria, E., Cuppone, F., Ciuffreda, L., Pino, M. S., Gelibter, A. J., Tortora, G., Cognetti, F., & Milella, M. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.607438 · Cited by 62
Kästner, J., Loeffler, H. H., Roberts, S. K., Martin-Fernandez, M. L., & Winn, M. (2009) · Journal of Structural Biology · doi:10.1016/j.jsb.2009.04.007 · Cited by 59
Kamar, F. G., & Posner, J. B. (2010) · Seminars in Neurology · doi:10.1055/s-0030-1255225 · Cited by 52
Docetaxel/anthracycline combinations for breast cancer treatment
von Minckwitz, G. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.4.485 · Cited by 50
Protein kinase Cε as a cancer marker and target for anticancer therapy
Totoń, E., Ignatowicz, E., Skrzeczkowska, K., & Rybczyńska, M. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70395-4 · Cited by 46
Overcoming Treatment Resistance in HER2-Positive Breast Cancer: Potential Strategies
Puglisi, F., Minisini, A. M., Angelis, C. D., & Arpino, G. (2012) · Drugs · doi:10.2165/11634000-000000000-00000 · Cited by 45
Smith, G. F. (2009) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(09)04801-2 · Cited by 42
Elevated Expression of the Tyrosine Phosphatase SHP-1 Defines a Subset of High-Grade Breast Tumors
Insabato, L., Amelio, I., Quarto, M., Zannetti, A., Tolino, F., de Mauro, G., Cerchia, L., Riccio, P., Baumhoer, D., Condorelli, G., et al. (2009) · Oncology · doi:10.1159/000276765 · Cited by 42
Cardiac ErbB-1/ErbB-2 mutant expression in young adult mice leads to cardiac dysfunction
Rajagopalan, V., Zucker, I. H., Jones, J. A., Carlson, M., & Ma, Y. J. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.91436.2007 · Cited by 42
Macdonald-Obermann, J. L., Adak, S., Landgraf, R., Piwnica-Worms, D. R., & PIKE, L. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.489534 · Cited by 40
Finding the missing links in EGFR
Bessman, N. J., & Lemmon, M. A. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2221 · Cited by 39
Roskoski, R. J. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.813015 · Cited by 39
Self-citationPancreatic Cancer: Medical Management (Novel Chemotherapeutics)
Páez, D., LaBonte, M. J., & Lenz, H. (2012) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2011.12.004 · Cited by 36
Verma, S., & Ewer, M. S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq607 · Cited by 36
Rules and Guidelines for Mouse Gene, Allele, and Mutation Nomenclature: A Condensed Version
Maltais, L. J., Blake, J. A., Chu, T., Lutz, C. M., Eppig, J. T., & Jackson, I. J. (2002) · Genomics · doi:10.1006/geno.2002.6747 · Cited by 35
Directed in vivo angiogenesis assay and the study of systemic neoangiogenesis in cancer
Claudio Napoli, A., Giordano, A., Casamassimi, A., Pentimalli, F., Ignarro, L. J., & de Nigris, F. (2010) · International Journal of Cancer · doi:10.1002/ijc.25743 · Cited by 26
Optimal Therapy of Advanced Hodgkin Lymphoma
Advani, R. H. (2011) · Hematology · doi:10.1182/asheducation-2011.1.310 · Cited by 24
Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab
Brand, T. M., Dunn, E., Iida, M., Myers, R. A., Kostopoulos, K. T., Li, C., Peet, C. R., & Wheeler, D. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.5.16394 · Cited by 20
PKCη is a novel prognostic marker in non-small cell lung cancer.
Krasnitsky, E., Baumfeld, Y., Freedman, J., Sion‐Vardy, N., Ariad, S., Novack, V., & Livneh, E. (2012) · PubMed · Cited by 19
Kantarjian, H. M., & O'Brien, S. M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00190-1 · Cited by 17
Molecular Characteristics and Pathways of Avastin for the Treatment of Glioblastoma Multiforme
Spasić, M., Chow, F. E., Tu, C., Nagasawa, D. T., & Yang, I. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.05.002 · Cited by 16
Critical appraisal of the use of regorafenib in the management of colorectal cancer
Morgillo, F., Festino, Fabozzi, Gambardella, V., Martinelli, Troiani, T., Vita, D., Orditura, M., Ciardiello, F., & Manzo (2013) · Cancer Management and Research · doi:10.2147/cmar.s34281 · Cited by 9
Selection of Therapy: Rational Decisions Based on Molecular Events
Khorashad, J. S., & Deininger, M. W. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.09.006 · Cited by 8
Ma, Y. T., Cullen, M. H., & Hussain, S. A. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.03.004 · Cited by 8
Cited by
A living biobank of breast cancer organoids captures disease heterogeneity
Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A. V., Wind, K., Gracanin, A., Begthel, H., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.010 · Cited by 1,973
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., et al. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.001 · Cited by 1,486
Metadata
- Authors
- Roskoski, R.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 79
- Pages
- 34-74
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2070727232
- Cited by
- 1,353
- References
- 288
- FWCI
- 36.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.